• No exit: targeting the budding process to inhibit filovirus replication. Harty, RN. Antiviral Res. 2009 Mar;81(3):189-97. doi: 10.1016/j.antiviral.2008.12.003. Epub 2008 Dec 27. Review. PubMed PMID: 19114059;PubMed Central PMCID: PMC2666966.
  • The multifunctional Ebola virus VP40 matrix protein is a promising therapeutic target. Madara JJ, Han Z, Ruthel G, Freedman BD, Harty RN. Future Virol. 2015 May;10(5):537-546. PubMed PMID: 26120351; PubMed Central PMCID: PMC4480923.
  • Small-molecule probes targeting the viral PPxY-host Nedd4 interface block egress of a broad range of RNA viruses. Han Z, Lu J, Liu Y, Davis B, Lee MS, Olson MA, Ruthel G, Freedman BD, Schnell MJ, Wrobel JE, Reitz AB, Harty RN. J Virol.  2014 Jul;88(13):7294-306. doi: 10.1128/JVI.00591-14. Epub 2014 Apr 16. PubMed PMID: 24741084; PubMed Central PMCID: PMC4054416.
  • Conserved motifs within Ebola and Marburg virus VP40 proteins are important for stability, localization, and subsequent budding of virus-like particles. Liu Y, Cocka L, Okumura A, Zhang YA, Sunyer JO, Harty RN. J Virol. 2010 Mar;84(5):2294-303. doi: 10.1128/JVI.02034-09. Epub 2009 Dec 23. PubMed PMID:20032189; PubMed Central PMCID: PMC2820906
  • Quinoxaline-based inhibitors of Ebola and Marburg VP40 egress. Loughran HM, Han Z, Wrobel JE, Decker SE, Ruthel G, Freedman BD, Harty RN, Reitz AB. . Bioorg Med Chem Lett. 2016 Aug 1;26(15):3429-35. doi: 10.1016/j.bmcl.2016.06.053. Epub 2016 Jun 23. PubMed PMID: 27377328; PubMed Central PMCID: PMC4955528
  • A PPxY motif within the VP40 protein of Ebola virus interacts physically and functionally with a ubiquitin ligase: implications for filovirus budding. Harty RN, Brown ME, Wang G, Huibregtse J, Hayes FP. Proc Natl Acad Sci U S A. 2000 Dec 5;97(25):13871-6. PubMed PMID: 11095724; PubMed Central PMCID: PMC17668.